Axsome Therapeutics (AXSM) Change in Receivables (2022 - 2026)

Axsome Therapeutics' Change in Receivables history runs 5 years deep, the most recent figure standing at $26.6 million for Q1 2026.

• In Q1 2026, Change in Receivables rose 37.13% year-over-year to $26.6 million; the TTM figure through Mar 2026 stood at $89.7 million (up 49.54% YoY), while the FY2025 annual figure was $82.5 million, up 74.78% from the prior year.
• Change in Receivables came in at $26.6 million for Q1 2026 at Axsome Therapeutics, down from $28.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $37.4 million in Q2 2025 to a low of -$2.3 million in Q3 2025.
• A 5-year average of $15.7 million and a median of $17.4 million in 2022 frame the typical range for Change in Receivables.
• On a YoY basis, Change in Receivables climbed as much as 193.21% in 2025 and fell as far as 161.75% in 2025.
• Axsome Therapeutics' Change in Receivables stood at $17.4 million in 2022, then declined by 5.7% to $16.4 million in 2023, then advanced by 9.14% to $17.9 million in 2024, then surged by 56.14% to $28.0 million in 2025, then declined by 4.86% to $26.6 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $26.6 million, $28.0 million, and -$2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison